01-09-2022 | Metformin | News
People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.
31-08-2022 | Heart failure | News
SGLT2 inhibitors reduce the risk for adverse outcomes in a broad range of patients with heart failure, suggest findings from a meta-analysis of five randomized placebo-controlled trials.
21-07-2022 | Sotagliflozin | News
The only notable short-term differences in the effects of sotagliflozin and empagliflozin occur in glucose metabolism after breakfast, show findings from a randomized trial.
02-09-2022 | Dapagliflozin | News
27-08-2022 | Dapagliflozin | News
25-08-2022 | Physical activity | News
18-08-2022 | Finerenone | News
Ian de Boer joins Amrit Lamba to discuss how these medications will influence the treatment of kidney disease in people with DKD.
07-06-2022 | ADA 2022 | Conference coverage | News
27-05-2022 | SGLT2 inhibitors | News
18-05-2022 | Empagliflozin | News
25-04-2022 | Dapagliflozin | News
12-04-2022 | SGLT2 inhibitors | News
05-04-2022 | Medications | At a glance | Article
Get the latest developments in diabetes delivered straight to your inbox
Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.